Your browser doesn't support javascript.
loading
Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells.
Jeon, Min Ji; Kim, Won Gu; Lim, Seonhee; Choi, Hyun-Jeung; Sim, Soyoung; Kim, Tae Yong; Shong, Young Kee; Kim, Won Bae.
Affiliation
  • Jeon MJ; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kim WG; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Lim S; Asan Institute of Life Sciences, Seoul, South Korea.
  • Choi HJ; Asan Institute of Life Sciences, Seoul, South Korea.
  • Sim S; Asan Institute of Life Sciences, Seoul, South Korea.
  • Kim TY; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Shong YK; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kim WB; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: kimwb@amc.seoul.kr.
Mol Cell Endocrinol ; 419: 113-23, 2016 Jan 05.
Article in En | MEDLINE | ID: mdl-26463583
ABSTRACT
The naturally occurring short-chain fatty acid, α-lipoic acid (ALA) is a powerful antioxidant which is clinically used for treatment of diabetic neuropathy. Recent studies suggested the possibility of ALA as a potential anti-cancer agent, because it could activate adenosine monophosphate activated protein kinase (AMPK) and inhibit transforming growth factor-ß (TGFß) pathway. In this study, we evaluate the effects of ALA on thyroid cancer cell proliferation, migration and invasion. We performed in vitro cell proliferation analysis using BCPAP, HTH-83, CAL-62 and FTC-133 cells. ALA suppressed thyroid cancer cell proliferation through activation of AMPK and subsequent down-regulation of mammalian target of rapamycin (mTOR)-S6 signaling pathway. Low-dose ALA, which had minimal effects on cell proliferation, also decreased cell migration and invasion of BCPAP, CAL-62 and HTH-83 cells. ALA inhibited epithelial mesenchymal transition (EMT) evidently by increase of E-cadherin and decreases of activated ß-catenin, vimentin, snail, and twist in these cells. ALA suppressed TGFß production and inhibited induction of p-Smad2 and twist by TGFß1 or TGFß2. These findings indicate that ALA reduces cancer cell migration and invasion through suppression of TGFß production and inhibition of TGFß signaling pathways in thyroid cancer cells. ALA also significantly suppressed tumor growth in mouse xenograft model using BCPAP and FTC-133 cells. This is the first study to show anti-cancer effect of ALA on thyroid cancer cells. ALA could be a potential therapeutic agent for treatment of advanced thyroid cancer, possibly as an adjuvant therapy with other systemic therapeutic agents.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Thyroid Neoplasms / Thioctic Acid / Epithelial-Mesenchymal Transition / Antineoplastic Agents Type of study: Prognostic_studies Language: En Journal: Mol Cell Endocrinol Year: 2016 Type: Article Affiliation country: South Korea

Full text: 1 Database: MEDLINE Main subject: Thyroid Neoplasms / Thioctic Acid / Epithelial-Mesenchymal Transition / Antineoplastic Agents Type of study: Prognostic_studies Language: En Journal: Mol Cell Endocrinol Year: 2016 Type: Article Affiliation country: South Korea